

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 19, 2025

InVivoMab anti-mouse ICOS

RRID:AB_1107622

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0059, RRID:AB_1107622)

Antibody Information

URL: http://antibodyregistry.org/AB_1107622

Proper Citation: (Bio X Cell Cat# BE0059, RRID:AB_1107622)

Target Antigen: ICOS

Host Organism: rat

Clonality: monoclonal

Comments: Applications: in vivo blocking of ICOS/ICOSL signaling, Flow cytometry

Antibody Name: InVivoMab anti-mouse ICOS

Description: This monoclonal targets ICOS

Target Organism: mouse

Clone ID: clone 7E.17G9

Antibody ID: AB_1107622

Vendor: Bio X Cell

Catalog Number: BE0059

Alternative Catalog Numbers: BE0059-5MG, BE0059-1MG, BE0059-50MG, BE0059-25MG, BE0059-100MG

Record Creation Time: 20231110T061455+0000

Record Last Update: 20241115T014617+0000

Ratings and Alerts

No rating or validation information has been found for InVivoMab anti-mouse ICOS.

No alerts have been found for InVivoMab anti-mouse ICOS.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Yadavilli S, et al. (2023) Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade. Cancer research communications, 3(8), 1564.

Cohen GS, et al. (2023) Transplantation elicits a clonally diverse CD8+ T cell response that is comprised of potent CD43+ effectors. Cell reports, 42(8), 112993.

Flamar AL, et al. (2020) Interleukin-33 Induces the Enzyme Tryptophan Hydroxylase 1 to Promote Inflammatory Group 2 Innate Lymphoid Cell-Mediated Immunity. Immunity, 52(4), 606.

Wang W, et al. (2018) RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. Cancer cell, 34(5), 757.

Bauché D, et al. (2018) LAG3+ Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1+ Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis. Immunity, 49(2), 342.